ClinicalTrials.gg
RecruitingNCT06422052Updated Dec 30, 2024

Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms

An observational study in Helicobacter Pylori Infection and Dyspepsia, sponsored by Shanghai Jiao Tong University School of Medicine. Recruiting at 26 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-30.

Sponsored by Shanghai Jiao Tong University School of Medicine · Observational

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,242
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The objectives of this multicenter, prospective, observational study were to investigate the incidence of dyspeptic symptoms in patients with Helicobacter pylori (H. pylori) infection and to continuously follow up the remission of dyspeptic symptoms after H. pylori eradication, so as to provide reference for the clinical diagnosis and treatment strategies of patients with H. pylori infection and dyspeptic symptoms.

02

Conditions studied

  • Helicobacter Pylori Infection
  • Dyspepsia

Browse trials for

Keywords

  • Helicobacter Pylori Infection
  • Dyspepsia
03

In context

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 67 are open to participants now.

This study's planned enrollment of 2,242 is above the median of 200 across 62 observational studies indexed under Dyspepsia.

Browse Dyspepsia studies →

Lead sponsor

Shanghai Jiao Tong University School of Medicine is the lead sponsor of 374 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population targets male and female patients aged 15-80 who have not previously been treated for Helicobacter pylori and have been diagnosed via 13C/14C urea breath test or gastroscopy. Participants must be willing and able to give informed consent. Exclusions include individuals under 18 or over 80, those with organic digestive diseases, pregnant or nursing women, those with a history of cancer or partial gastrectomy, and individuals with severe organ dysfunction or congenital diseases. Also excluded are those with symptoms like melena, hematemesis, anemia, or cachexia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 18-80 years
  • H. pylori infection diagnosed by 13C/ 14C-UBT (> 2 times the cutoff value) and/or gastroscopy (rapid urease strong positive and histological positive)
  • Treatment-naive patients with Helicobacter pylori
  • Ability and willingness to participate in the study and to sign and give

Exclusion criteria

Exclusion Criteria:

  • Under 18 or over 80 years old
  • Organic digestive diseases, such as active peptic ulcer, gastroesophageal reflux, gastrointestinal bleeding, acute/chronic pancreatitis, acute/chronic cholecystitis, gallstones, intestinal obstruction, inflammatory bowel disease, etc.
  • Combined with melena, hematemesis, anemia, emaciation and other alarm symptoms
  • Pregnant and lactating women
  • History of cancer
  • History of subtotal gastrectomy
  • Severe organ dysfunction of heart, liver, kidney, lung and other important organs and congenital diseases, such as grade IV heart failure, liver failure, uremia, respiratory failure, hemophilia, Wilson's disease, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,242 participants (estimated)
Patient registry
No

Groups and cohorts

  • Dyspepsia with Helicobacter pylori infection

    Other: Epidemiological questionnaire and Functional Dyspepsia Symptom Diary(FDSD)

Interventions

  • OtherEpidemiological questionnaire and Functional Dyspepsia Symptom Diary(FDSD)

    H. pylori infection was confirmed by 13C/ 14C-breath test and/or rapid urease test under endoscopy and histopathological examination. Epidemiological questionnaire and Functional Dyspepsia Symptom Diary (FDSD) were used to investigate basic information and assess dyspeptic symptoms. Patients with dyspepsia who successfully eradicated Helicobacter pylori infection will be followed up for dyspeptic symptoms after 2 months and 6 months to evaluate the relief of dyspeptic symptoms.

06

What researchers measure

Primary outcomes

  1. the incidence of dyspepsia in patients with Helicobacter pylori infection

    Proportion of patients with Helicobacter pylori infection with dyspeptic symptoms

    Time frame: Time 0 when finished the Epidemiological questionnaire and Functional Dyspepsia Symptom Diary

  2. Relief of Helicobacter pylori related dyspepsia

    The Functional Dyspepsia Symptom Diary (FDSD) will be used to evaluate the dyspepsia symptoms of the patients

    Time frame: Patients with dyspepsia who have successfully eradicated Helicobacter pylori infection will be followed up for dyspepsia symptoms after 2 months and after 6 months to assess the remission of dyspepsia symptoms

07

Study locations

26 of 26 sites recruiting
  • Chongqing Daping Hospital
    Chongqing, Chongqing, China
    Recruiting
    • Chunhui Lan · Contact+86 13896067955
  • The Ninth People's Hospital of Chongqing
    Chongqing, Chongqing, China
    Recruiting
    • Xiaoying Yuan · Contact+86 13983850146
  • The People's Hospital of Kaizhou District, CQ
    Chongqing, Chongqing, China
    Recruiting
    • Qiang Wu · Contact+8618223960853
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
    • Jinyan Zhang · Contact+8615160042319
  • The People's Hospital of Wuwei
    Wuwei, Gansu, China
    Recruiting
    • Xiaoyun Ma · Contact+8613639359150
  • The First People's Hospital of Qinzhou
    Qinzhou, Guangxi, China
    Recruiting
    • Meimei Zeng · Contact+8615107774335
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
    Recruiting
    • Yanli Bai · Contact+86 13653794460
  • Yongcheng People's Hospital of Henan Province
    Shangqiu, Henan, China
    Recruiting
    • Hongdan Ma · Contact+86 13781408747
  • Xuchang Central Hospital
    Xuchang, Henan, China
    Recruiting
    • Shilei Song · Contact+86 13837421261
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Jing Li · Contact+86 18827603030
  • Baotou Central Hospital
    Baotou, Inner Mongolia, China
    Recruiting
    • Qiang Liu · Contact+86 15174918099
  • Dalian Friendship Hospital
    Dalian, Liaoning, China
    Recruiting
    • Fucheng Wang · Contact+86 15542626166
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
    Recruiting
    • Lina Liang · Contact+8618098875591
  • Renji Hospital, School of Medicine, Shanghai Jiao Tong University
    Shanghai, Shanghai 200127, China
    Recruiting
  • Ruijin Hospital Luwan Branch
    Shanghai, Shanghai, China
    Recruiting
    • Xiong Zheng · Contact+86 18116292085
  • Shanghai Construction Group Hospital
    Shanghai, Shanghai, China
    Recruiting
    • Qi Liao · Contact+8613512128067
  • Shanghai East Hospital
    Shanghai, Shanghai, China
    Recruiting
    • Qinjuan Sun · Contact+86 13681667917
  • Shanghai Putuo Liqun Hospital
    Shanghai, Shanghai, China
    Recruiting
    • Lamei Teng · Contact+86 13817591903
  • Shanghai Songjiang Central Hospital
    Shanghai, Shanghai, China
    Recruiting
    • Jing Wang · Contact+86 18918289144
  • West China Fourth Hospital, Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Yan Ou · Contact+8615008228212
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
    Tianjing, Tianjing, China
    Recruiting
    • Lin Yan · Contact+86 18222835795
  • The Second People's Hospital of Kashgar, Xinjiang
    Kashgar, Xinjiang, China
    Recruiting
  • Second People's Hospital of Jinning District, Kunming City
    Kunming, Yunnan, China
    Recruiting
    • Zhouhua Li · Contact+8613769108442
  • Ningbo Hangzhou Bay Hospital
    Ningbo, Zhejiang, China
    Recruiting
    • Shuliang Zhao · Contact+057458993397
  • The People's Hospital of Shengzhou
    Ningbo, Zhejiang, China
    Recruiting
    • Shan Yu · Contact+8613456521442
  • Shengzhou People's Hospital
    Shaoxing, Zhejiang, China
    Recruiting
    • Shan Yu · Contact+86 13456521442
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06422052
Responsible party
Hong Lu, MD (Medical Doctor of Division of Gastroenterology and Hepatology of Renji Hospital,Professor of Medicine, RenJi Hospital) — Principal investigator
First posted
May 20, 2024
Start date
Mar 11, 2024
Primary completion
May 31, 2025 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Dec 30, 2024

Study contacts

Hong Lu, MD
Contact
hlu@sjtu.edu.cn
+8613611958022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion